✓

PublishedJuly 20, 2026

Last reviewedAugust 23, 2026

Medical Expert Profile

Vinay Prasad, MD, MPH

Hematologist-Oncologist · Professor · Evidence and Health-Policy Researcher

Vinay Prasad, MD, MPH, is a hematologist-oncologist and Professor of Epidemiology and Biostatistics and Medicine at the University of California, San Francisco. His work focuses on cancer-drug evidence, randomized trials, clinical decision-making, regulatory policy, medical reversal and the quality of evidence supporting new treatments.

MD, MPH University of California, San Francisco Former FDA CBER Director

UCSF profile ORCID Research laboratory YouTube PubMed research

Professional overview

About Dr. Prasad

His academic work examines how cancer treatments are tested, approved,
interpreted and adopted in clinical practice.

✦

Current UCSF role

Dr. Prasad is Professor of Epidemiology and Biostatistics and Medicine at UCSF
and a practicing hematologist-oncologist at San Francisco General Hospital.
His clinical work includes classic hematology, malignant hematology and solid tumors.

✦

FDA service

Before returning to UCSF in June 2026, he served at the U.S. Food and Drug Administration
as Chief Medical and Scientific Officer and Director of the Center for Biologics
Evaluation and Research.

Clinical and research areas

Areas of expertise

ClearMed Journal presents cancer-treatment claims according to the strength,
limitations and clinical relevance of the available evidence.

✦

Hematology and oncology

Evidence-based assessment of blood disorders, hematologic malignancies,
solid tumors and cancer-treatment decisions.

✦

Clinical trials

Randomized trials, trial design, bias, control groups, patient outcomes
and interpretation of study results.

✦

Cancer-drug evidence

Drug efficacy, safety, surrogate endpoints, accelerated approval,
value, pricing and post-approval evidence.

✦

Fenbendazole claims

Critical evaluation of claims involving fenbendazole, a veterinary antiparasitic
medicine that is not established as a safe or effective human cancer treatment.

✦

Regulatory policy

FDA standards, biologics oversight, drug approvals, evidence thresholds
and post-market responsibilities.

✦

Medical reversal

Study of established medical practices later found to be ineffective,
unsupported or less beneficial than originally believed.

Education and professional development

Medical training

Doctor of Medicine

University of Chicago Pritzker School of Medicine

RES

Internal medicine residency

Northwestern University

FEL

Hematology and medical oncology fellowship

National Cancer Institute and National Institutes of Health

MPH

Master of Public Health

Johns Hopkins University

Selected research themes

✓Randomized trials, bias and evidence quality
✓Cancer-drug approvals and surrogate endpoints
✓Clinical decision-making and health policy
✓Low-value care and medical reversal
✓Cancer-drug pricing, value and patient outcomes

Research and public communication

Professional contribution

Selected work

✓Author of more than 500 peer-reviewed papers
✓Co-author of Ending Medical Reversal
✓Author of Malignant: How Bad Policy and Bad Evidence Harm People with Cancer
✓Host of the Plenary Session oncology podcast
✓Research mentor and director of the VKPrasad Lab

Professional and medical sources

Readers can use these records to confirm the profile information
and review evidence on fenbendazole and cancer-treatment claims.

ClearMed Journal standards

Profile review & publication

Profile information reviewed and published by ClearMed Journal

Professional titles, training, expertise, roles and linked records are presented using the profile information and professional sources maintained for this expert.

Published: July 20, 2026Last reviewed: August 23, 2026Editorial status: Published

01Credential review

Professional information is organised against linked records.

02Source transparency

Readers can open professional, academic or scholarly references.

03Role transparency

Writing and medical-review relationships are displayed separately.

04Editorial updates

Profiles can be revised when material professional information changes.

Medical information notice: This profile and related articles provide general educational information and do not replace diagnosis, treatment or advice from a licensed oncology team. Fenbendazole is primarily a veterinary antiparasitic medicine; it is not an established or FDA-approved human cancer treatment. People with cancer should not replace proven treatment or clinical-trial care with veterinary products or unverified online protocols.